Trial Information - Phase III
OVELIA: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Disease Specifics: HER2- premenopausal
Protocol ID: TOL2506A
Sponsor: Tolmar, Inc
Status: PENDING OPEN
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
